胃癌术后腹腔热灌注联合静脉化疗的应用研究

目的研究胃癌术后腹腔热灌注化疗联合静脉化疗的治疗效果。方法140例胃癌根治术后患者随机分为腹腔热灌注组(n=72)和静脉化疗组(n=68)。腹腔热灌注组患者在静脉化疗同时应用腹腔热灌注化疗,观察两组术后并发症、不良反应、术后生存率及腹腔复发率。结果两组在术后并发症及不良反应无显著性差异。术后3、5年生存率腹腔热灌注组和静脉化疗组分别为86.1%、60.2%和58.3%、29.4%(P<0.05);术后3、5年腹腔复发率分别为5.6%、27.8%和20.6%、53%(P<0.05)。结论胃癌术后腹腔热灌注联合静脉化疗可有效控制复发和转移,提高胃癌术后病人的生存率和生存质量。

Clinical study of postoperative intraperitoneal hyperthermic perfusion combined with venoclysis for gastric cancer

Objective:To study the effect of intraperitoneal hyperthermic perfusion chemotherapy combined with venoclysis on postoperative gastric cancer.Methods:140 postoperative patients with gastric cancer were divided into IPHPC group(n=72) and chemotherapy of venoclysis group(n=68).The intraperitoneal hyperthermic perfusion chemotherapy and chemotherapy of venoclysis were applied for the patients in IPHPC group at one time.Postoperative complications,toxicity,survival rate and peritoneal recurrence rate in two groups were observed.Results:There was no sharp difference in the postoperative complications and toxicity between the two groups.The 3,5 year-survival rate were 86.1%,60.2% and 58.3%,29.4% in IPHPC group and CV group.The 3,5 year-peritoneal cavity recurrence rate were 5.6%,20.6%and 27.8%,53% in IPHPC group and CV group.There were significant differences in survival rate and peritoneal recurrence rate between the two groups.Conclusion:Intraperitoneal hyperthermic perfusion chemotherapy combined with venoclysis can prevent recurrence and metastasis effectively,and improve the survival rate and quality of life of postoperative gastric cancer patients.